Dr. Rolfo Discusses the Potential Utility of Ceritinib

Video

Christian Rolfo, MD, PhD, MHBA, head, phase I clinical trials unit, Antwerp University Hospital, Belgium, discusses the potential utility of ceritinib.

Christian Rolfo, MD, PhD, MHBA, head, phase I clinical trials unit, Antwerp University Hospital, Belgium, discusses the potential utility of ceritinib.

The most important potential for ceritinib is related to the activity seen in naïve patients. Rolfo says there is a possibility to use this agent early on.

There are also new combinations with ceritinib evaluating the potential to overcome resistance. Unfortunately, even with new promising agents, there is always a possibility of recurrence through mutations or transformations.

Related Videos
Mike Lattanzi, MD, medical oncologist, Texas Oncology
Vikram M. Narayan, MD, assistant professor, Department of Urology, Emory University School of Medicine, Winship Cancer Institute; director, Urologic Oncology, Grady Memorial Hospital
Stephen V. Liu, MD
S. Vincent Rajkumar, MD
Pashtoon Murtaza Kasi, MD, MS
Naseema Gangat, MBBS
Samilia Obeng-Gyasi, MD, MPH,
Kian-Huat Lim, MD, PhD
Saurabh Dahiya, MD, FACP, associate professor, medicine (blood and marrow transplantation and cellular therapy), Stanford University School of Medicine, clinical director, Cancer Cell Therapy, Stanford BMT and Cell Therapy Division
Muhamed Baljevic, MD